BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
2.237
+0.007 (0.32%)
Mar 13, 2026, 12:11 PM EDT - Market open

BioNexus Gene Lab Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
9.479.519.7710.9313.3611.39
Revenue Growth (YoY)
2.21%-2.66%-10.60%-18.21%17.31%8872.03%
Cost of Revenue
8.078.228.449.6711.19.67
Gross Profit
1.41.291.331.262.271.72
Selling, General & Admin
1.9943.041.731.281.33
Research & Development
0.060.050.05---
Other Operating Expenses
1.10.881.31---
Total Operating Expenses
3.144.944.411.731.281.33
Operating Income
-2.35-1.57-2.59-0.291.061.27
Interest Income
0.140.220.13---
Interest Expense
-0.02-0.02-0.01-0.01-0.01-0.01
Other Non-Operating Income (Expense)
2.033.930.840.180.070.89
Total Non-Operating Income (Expense)
2.154.120.960.170.050.88
Pretax Income
-2.37-1.59-2.61-0.31.041.26
Provision for Income Taxes
---0.050.290.17
Net Income
-2.3-1.6-2.63-0.360.751.09
Net Income to Common
-2.3-1.6-2.63-0.360.751.09
Net Income Growth
-----31.31%-
Shares Outstanding (Basic)
221816111
Shares Outstanding (Diluted)
221816111
Shares Change (YoY)
9.16%12.24%1001.72%0.99%66.36%19.16%
EPS (Basic)
-0.16-0.09-0.17-0.460.481.44
EPS (Diluted)
-0.16-0.09-0.17-0.460.481.44
EPS Growth
-----66.67%-
Free Cash Flow
-2.91-2.46-1.970.50.010.13
Free Cash Flow Growth
---8195.57%-95.42%-
Free Cash Flow Per Share
-0.13-0.14-0.120.350.000.15
Gross Margin
14.77%13.56%13.61%11.52%16.96%15.10%
Operating Margin
-24.81%-16.55%-26.54%-2.66%7.90%11.18%
Profit Margin
-25.05%-16.77%-26.69%-3.26%5.62%9.61%
FCF Margin
-30.74%-25.88%-20.18%4.55%0.04%1.15%
EBITDA
-2.18-1.42-2.49-0.191.161.38
EBITDA Margin
-23.04%-14.94%-25.43%-1.70%8.71%12.08%
EBIT
-2.35-1.57-2.59-0.291.061.27
EBIT Margin
-24.81%-16.55%-26.54%-2.66%7.90%11.18%
Effective Tax Rate
-0.00%0.00%-17.23%27.93%13.34%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q